Generic Peptide Name,Application,Indication,sequence,SMILE code,SMILES A/B,Unnamed: 7,Molar Mass (g/mol),Constitutional members,Natural amino acids,D-Aas,cycle,Members/Macrocycle,Bond to form cycle,Lipidation,Glycosylation,half_life_seconds,Protein Binding,Bioavailability,Route of Administration,Country ,Agency,Year ,Design,Origin,Production Method,1,2,3,4,5,6,7,8,9,10,modifications,is_mod
Eptifibatide,Therapeutic,Treatment of myocardial infarction and acute coronary syndrome,XXGDWPC-NH2,C1C[C@H]2C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N,A,B,831.97,7,5,0,yes,7,side chain-to-side chain (disulfide),no,no,9000.0,25%,-,IV,US,FDA,1998,Analogue,Disintegrin protein from venom of the Southeastern pygmy rattlesnake,Synthesis - Liquid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB00063,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779265/,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020718s034lbl.pdf,https://www.ema.europa.eu/en/documents/product-information/integrilin-epar-product-information_en.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20718_Integrilin.cfm,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020718s034lbl.pdf,,,,,"deamino, NH2",True
Secretin Human,Diagnostic,"Indicated for stimulation of pancreatic secretions and gastric secretions for diagnosis of pancreatic dysfunction, and gastrinoma.",HSDGTFTSELSRLREGARLQRLLQGLV-NH2,C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CN=CN2)N)O,A,B,3039.458,27,27,0,no,N.A.,N.A.,no,no,2700.0,-,"Following intravenous bolus administration of 0.4 mcg/kg, synthetic human secretin concentration rapidly declines to baseline secretin levels within 90 to 120 minutes",IV,Canada,CADTH,1990,Natural,Secretin,Synthesis,https://go.drugbank.com/drugs/DB09532,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-256_Synthetic%20Human%20Secretin_Prntlbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021256s002lbl.pdf,,,,,,,,"H, NH2",True
Thymalfasin,Therapeutic (orphan),"Treatment of Hepatitis B and C, and to boost immuno response in treatment of other diseases.",Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN,CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)C,A,B,3108.315,28,28,0,no,N.A.,N.A.,no,no,7200.0,-,Rapidly absorbed with peak serum levels achieved at approximately 2 hours.,"IM, SC",US (Orphan approval),-,-,Natural,Thymosin alpha 1,Synthesis - Solid Phase and Liquid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB04900,https://pubchem.ncbi.nlm.nih.gov/compound/Thymalfasin,https://www.medscape.com/viewarticle/531601,https://patents.justia.com/patent/4466918,,,,,,,"acetyl, OH",True
Nesiritide,Therapeutic,Treatment of acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion,SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH,CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCCN)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CO)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC4=CNC=N4)C(=O)O)CC(C)C)CO)CO)CO)CO,A,B,3464.07,32,32,0,yes,17,side chain-to-side chain (disulfide),no,no,1080.0,-,"As a peptide, nesiritide has poor bioavailability and therefore is only available for intravenous administration.",IV,US,FDA,2001,Natural,Human B-type natriuretic peptide,Recombinant DNA technology,https://go.drugbank.com/drugs/DB04899,https://cvpharmacology.com/diuretic/natriuretics,https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020920s012lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020920s036lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-920_Natrecor.cfm,,,,,,"H, OH",True
Liraglutide,Therapeutic,Indicated in combination with diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus,HAEGTFTSDVSSYLEGQAAK(EX)EFIAWLVRGRG,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N)C(=O)O,A,B,3751.262,33,32,0,no,N.A.,N.A.,yes,no,46800.0,>98%,55%,SC,EU,EMA,2009,Analogue,Glucagon-like peptide-1 (GLP-1),Semisynthesis (recombinant DNA tecnhology + synthesis),https://go.drugbank.com/drugs/DB06655,,https://www.ema.europa.eu/en/documents/assessment-report/saxenda-epar-public-assessment-report_en.pdf,https://www.ema.europa.eu/en/documents/assessment-report/victoza-epar-public-assessment-report_en.pdf,https://www.ema.europa.eu/en/medicines/human/EPAR/victoza,,,,,,"H, OH",True
Pramlintide,Therapeutic,Treatment of diabetes mellitus types 1 and 2 as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.,KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY-NH2,[H]N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@]([H])(NC(=O)[C@H](C)NC(=O)[C@@]([H])(NC(=O)[C@H](CC(N)=O)NC1=O)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@]([H])([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O,A,B,3949.44,37,37,0,yes,6,side chain-to-side chain (disulfide),no,no,2880.0,Pramlintide does not extensively bind to blood cells or albumin (approximately 40% of the drug is unbound in plasma).,30-40%,SC,US,FDA,2005,Analogue,Amylin,Synthesis - Solid Phase Peptide Synthesis using fragments,https://go.drugbank.com/drugs/DB01278,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin%20Injection_pharmr.PDF,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin.cfm,https://patents.google.com/patent/US20100249370?oq=US20100249370,,,,,,,"H, NH2",True
Exenatide,Therapeutic,Indicated for improving glycemic control in adults with type 2 diabetes mellitus along with diet and exercise,HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2,CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC9=CNC=N9)N,A,B,4186.63,39,39,0,no,N.A.,N.A.,no,no,8640.0,Not determined,"Because exenatide is administerd subcutaneously, the bioavailability is 1.",SC,US,FDA,2005,Analogue,Glucagon-like peptide-1 (GLP-1),Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB01276,https://www.ema.europa.eu/en/documents/scientific-discussion/byetta-epar-scientific-discussion_en.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021773s007lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_ByettaTOC.cfm,https://www.ema.europa.eu/en/documents/scientific-discussion/byetta-epar-scientific-discussion_en.pdf ,,,,,,"H, NH2",True
Terlipressin,Therapeutic,Used to stop bleeding of varices in the food pipe (oesophagus) (2012) and to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function (2022).,GGGCYFQNCPKG-NH2,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,A,A,1227.38,12,12,0,yes,6,side chain-to-side chain (disulfide),no,no,3000.0,30%,-,IV,Australia,TGA-FDA,2012 and 2022,Analogue,Vasopressin,Synthesis - Solid Phase Peptide Synthesis and Post Synthesis Cyclisation,https://go.drugbank.com/drugs/DB02638,https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2044.2004.03877.x,https://www.fda.gov/media/139965/download,https://adisinsight.springer.com/drugs/800020856,https://patents.google.com/patent/US20060276626A1/en?q=(felypressin)&oq=felypressin ,,,,,,"H, NH2",True
Lisinopril,Therapeutic,"Indicated for the treatment of acute myocardial infarction, hypertension, and as an adjunct therapy for heart failure",XKP,NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,A,B,405.495,3,2,0,no,N.A.,N.A.,no,no,168120.0,0%,25%,ORAL,US,FDA,1987,Heterologous,ACE inhibitor,Synthesis - Organic synthesis,https://go.drugbank.com/drugs/DB00722,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019777s054lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019558s060lbl.pdf,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871180/ ,,,,,,,"4-phenylbutanoyl, OH",True
Nafarelin,Therapeutic,"For treatment of central precocious puberty (true precocious puberty, GnRH-dependent precocious precocity, complete isosexual precocity) in children of both sexes and for the treatment of endometriosis.",XHWSYXLRPG-NH2,CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,A,B,1322.496,10,8,1,no,N.A.,N.A.,no,no,10800.0,80%,2.8%,NASAL,US,FDA,1990,Analogue,Gonadotropin-releasing hormone (GnRH),Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB00666,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019886s033s035lbl.pdf,https://www.drugs.com/availability/generic-synarel.html,https://gpatindia.com/nafarelin-synthesis-sar-mcqstructurechemical-properties-and-therapeutic-uses/ ,,,,,,,"pyroglutamyl, NH2",True
Carperitide,Therapeutic,Treatment of acute heart failure,SLRRSSCFGGRMDRIGAQSGLGCNSFRY,CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)O)CC(C)C)CO)CCC(=O)N)C,A,B,3080.48,28,28,0,yes,17,side chain-to-side chain (disulfide),no,no,120.0,-,-,IV,JP,PMDA,1995,Natural,Atrial natriuretic peptide,Recombinant DNA technology and Synthesis - Hybrid Solid Phase-Liquid Phase Peptide Synthesis,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396233/,https://www.pharmacodia.com/yaodu/html/v1/biologics/26a95a5834c46c93a5c200bfc6da212f.html,https://doi.org/10.1016/j.jjcc.2010.08.001,https://patents.google.com/patent/CN103880946A/en,,,,,,,"H, OH",True
Cetrorelix,Therapeutic,For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation,Ac-XXXSYXLRPa-NH2,CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,A,B,1431.06,10,5,5,no,N.A.,N.A.,no,no,226080.0,86%,85%,SC,EU,EMA,1999,Analogue,Gonadotropin-releasing hormone (GnRH),Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB00050,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021197s010lbl.pdf,https://www.ema.europa.eu/en/documents/product-information/cetrotide-epar-product-information_en.pdf,https://patents.google.com/patent/CN104610433A/en,,,,,,,"acetyl, NH2",True
Ganirelix,Therapeutic,For the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.,Ac-XXXSYXLXPa-NH2,CCNC(NCC)=NCCCC[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,A,B,1570.35,10,4,5,no,N.A.,N.A.,no,no,58320.0,81.9%,91.3%,SC,US,FDA,1999,Analogue,Gonadotropin-releasing hormone (GnRH),Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB06785,https://pubmed.ncbi.nlm.nih.gov/10593371/,https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21057lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021057s010lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21057_Antagon.cfm,"Rabasseda, X., Leeson, P., Castaner, J., Drugs of the Future v. 24, n. 4  (1999) : 0393, DOI: 10.1358/dof.1999.024.04.524868 ",,,,,"acetyl, NH2",True
Atosiban,Therapeutic,Used in delaying imminent pre-term birth in pregnant adult women ,XXITNCPXG-NH2,[H][C@]1(NC(=O)[C@@]([H])(NC(=O)[C@@H](CC2=CC=C(OCC)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)[C@@H](C)CC)[C@@H](C)O,A,A,994.19,9,6,1,yes,6,side chain-to-side chain (disulfide),no,no,6120.0,46-48%,"The bioavailability of atosiban is poor after intranasal administration. In contrast, high (97±17%) and linear to the dose absorption was demonstrated after s.c. administration, though with some inter- subject variability.",IV,EU,EMA,2000,Analogue,Oxytocin-Vasopressin,Synthesis - Liquid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB09059,https://www.ema.europa.eu/en/documents/scientific-discussion/tractocile-epar-scientific-discussion_en.pdf,https://www.ema.europa.eu/en/documents/scientific-discussion/tractocile-epar-scientific-discussion_en.pdf,https://www.ema.europa.eu/en/medicines/human/EPAR/tractocile,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951825/#:~:text=A%20solution%20synthesis%20route%2C%20which,the%20liquid%20synthesis%20%5B9%5D.",,,,,,"deamino, NH2",True
Taltirelin,Therapeutic,Taltirelin is primarily being researched for the treatment of spinocerebellar ataxia,XHP,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N,A,B,405.415,3,2,0,no,N.A.,N.A.,no,no,7140.0,-,-,ORAL,JP,PMDA,2000,Analogue,Thyrotropin-releasing hormone (TRH),Synthesis - Solid Phase Peptide Synthesis,https://newdrugapprovals.org/tag/taltirelin/,"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1527-3458.1998.tb00039.x#:~:text=The%20plasma%20half%2Dlife%20(t1,h%20after%20administration%20(45).",https://pubmed.ncbi.nlm.nih.gov/15931571/,https://patents.google.com/patent/KR101574252B1/en,,,,,,,"1-methyl-2,6-dioxohexahydropyrimidyl, NH2",True
Aviptadil,Therapeutic (orphan),Erectile dysfunction (in combination with phentolamine),HSDAVFTDNYTRLRKQMAVKKYLNSILN,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1)C(C)C)[C@@H](C)O)[C@H](O)CC)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O,B,B,3255.75,28,28,0,no,N.A.,N.A.,no,no,102.0,-,-,Intracavernous injection,New Zealand,MedSafe,2000,Natural,Vasoactive intestinal peptide (VIP),Synthesis - Hybrid Solid Phase-Liquid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB06260,https://www.mims.co.uk/aviptadil-phentolamine-launched-combination-treatment-erectile-dysfunction/mens-health/article/1370338,https://bnf.nice.org.uk/drug/aviptadil-with-phentolamine-mesilate.html,http://mri.cts-mrp.eu/download/DK_H_2351_001_FinalSPC.pdf,https://pubmed.ncbi.nlm.nih.gov/11566015/,https://patents.google.com/patent/CN104447963A/en ,,,,,"H, OH",True
Carbetocin,Therapeutic,Used to control postpartum hemorrhage and bleeding after giving birth.,XXIQNCPLG-NH2,[H][C@]1(NC(=O)[C@H](CC2=CC=C(OC)C=C2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)CC,A,A,988.17,9,7,0,yes,6,thioether,no,no,2400.0,,80% (IM),"IV, IM",Canada-UK,CADTH-MHRA,1997,Analogue,Oxytocin,Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB01282,https://pubchem.ncbi.nlm.nih.gov/compound/Carbetocin,https://gp2u.com.au/static/pdf/D/DURATOCIN-PI.pdf,https://www.who.int/selection_medicines/committees/expert/22/applications/s22.1_carbetocin.pdf,https://patents.google.com/patent/CN104592362A/en,,,,,,"butyril , NH2",True
Ziconotide,Therapeutic,"Ziconotide is indicated for the management of severe chronic pain in patients refractory to other treatments, and for whom intrathecal therapy is warranted",C(1)KGKGAKC(2)SRLMYDC(3)C(1)TGSC(2)RSGKC(3)-NH2,C[C@H]1C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N1)CCCCN)CCCCN)N)C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N3)CO)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CCCNC(=N)N)CC(C)C)CCSC)CC4=CC=C(C=C4)O)CC(=O)O)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCCCN,A,B,2639.14,25,25,0,yes,multicyclic,3 side chain-to-side chain (disulfide),no,no,16560.0,50%,-,IT,US,FDA,2004,Natural,ω-conotoxin peptide,Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB06283,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021060s003lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021060s003lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-060_Prialt.cfm,https://patents.google.com/patent/CN102268082B/en,,,,,,"H, NH2",True
Mifamurtide,Therapeutic,"Indicated in children, adolescents and young adults for the treatment of high-grade, resectable, non-metastatic osteosarcoma after macroscopically complete surgical resection, typically in combination with post-operative multi-agent chemotherapy",XAXAX,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(=O)N)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]([C@H](C=O)NC(=O)C)[C@@H]([C@@H](CO)O)O)OC(=O)CCCCCCCCCCCCCCC,A,B,1237.518,5,2,0,no,N.A.,N.A.,yes,yes,64800.0,,"Due to rapid clearance from plasma, administration of mifamurtide is associated with a very low serum concentration of total (liposomal and free) drug. The mean AUC was 17.0 ± 4.86 h x nM and peak plasma concentration (Cmax) was 15.7 ± 3.72 nM following intravenous administration of 4 mg mifamurtide in healthy adult subjects",IV,EU,EMA,2009,Analogue,Muramyl dipeptide,Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB13615,https://www.ema.europa.eu/en/documents/product-information/mepact-epar-product-information_en.pdf,https://www.ema.europa.eu/en/documents/product-information/mepact-epar-product-information_en.pdf,https://www.ema.europa.eu/en/medicines/human/EPAR/mepact,https://patents.google.com/patent/CN103408635A/en ,,,,,,"N-acetylmuramoyl, dipalmitoyl phosphatidyl ethanolamine",True
Pasireotide,Therapeutic,For the treatment of Cushing’s disease,XXXwKXF,NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1,A,A,1047.227,7,2,1,yes,6,head-to-tail,no,no,43200.0,88%,Absolute bioavailability of pasireotide was not evaluated in humans and it was predicted to be low (<5%) from in vitro studies with low permeability.,"SC, IM",EU,EMA,2012,Analogue,Somatostatin,Synthesis - Liquid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB06663,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/200677Orig1s000ClinPharmR.pdf,https://www.ema.europa.eu/en/documents/assessment-report/signifor-epar-public-assessment-report_en.pdf,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu309671,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600510/#:~:text=The%20liquid%2Dphase%20total%20synthesis,as%20the%20final%20cyclization%20position. ",,,,,,"cycle, cycle",True
Lixisenatide,Therapeutic,Used as antihyperglycemic agent for treatment of type 2 diabetes mellitus (T2DM),HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2,CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC8=CNC=N8)N,A,B,4858.56,44,44,0,no,N.A.,N.A.,no,no,10800.0,55%,-,SC,EU,EMA,2013,Analogue,Glucagon-like peptide-1 (GLP-1),Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB09265,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208471Orig1s000SumR.pdf,https://www.ema.europa.eu/en/documents/assessment-report/lyxumia-epar-public-assessment-report_en.pdf,https://www.ema.europa.eu/en/medicines/human/EPAR/lyxumia,https://patents.google.com/patent/CN103709243A/en ,,,,,,"H, NH2",True
Afamelanotide,Therapeutic,Indicated for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP),Ac-SYSXEHfRWGKPV-NH2,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O,A,B,1646.874,13,11,1,no,N.A.,N.A.,no,no,1800.0,-,-,SC,EU,EMA,2014,Analogue,Alpha-melanocyte stimulating hormone (α-MSH),Synthesis - Liquid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB04931,https://www.ema.europa.eu/en/documents/assessment-report/scenesse-epar-public-assessment-report_en.pdf,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu308541,https://www.ema.europa.eu/en/documents/assessment-report/scenesse-epar-public-assessment-report_en.pdf ,,,,,,,"acetyl, NH2",True
Oritavancin,Therapeutic,Treatment of skin infections,-,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(NCC5=CC=C(C=C5)C5=CC=C(Cl)C=C5)[C@@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2,B,B,1793.12,N.A.,N.A.,N.A.,yes,multicyclic,C-O-C; C-C,yes,yes - 3 sugars,882000.0,85%,-,IV,US,FDA,2014,Analogue,Vancomycin,Semisynthesis (fermentation + synthesis),https://go.drugbank.com/drugs/DB04911,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206334s000lbl.pdf,https://www.ema.europa.eu/en/documents/assessment-report/orbactiv-epar-public-assessment-report_en.pdf,https://patents.google.com/patent/CN109053864B/en ,,,,,,,"CH3, OH",True
Sincalide,Diagnostic,"As the product Kinevac (FDA), sincalide is used for the following indications: 1) to stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; (2) to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; (3) to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.",DXMGWMDF-NH2,CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)N,A,B,1143.27,8,7,0,no,N.A.,N.A.,no,no,120.0,-,100% (IV),IV,US,FDA,1976,Analogue,Cholecystokinin,Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB09142,https://pubchem.ncbi.nlm.nih.gov/compound/Sincalide,http://tech.snmjournals.org/content/early/2018/08/02/jnmt.118.215038.full.pdf,https://patents.google.com/patent/CN104987362A/en ,,,,,,,"H, NH2",True
Semaglutide,Therapeutic,"Indicated to improve glycemic control in adults with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise.",H-XEGTFTSDVSSYLEGQAAK-(XXEX)-EFIAWLVRGRG,CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N,A,B,4113.641,35,31,0,no,N.A.,N.A.,yes,no,604800.0,99% (albumin),89%,"SC, ORAL",US,FDA,2017,Analogue,Glucagon-like peptide-1 (GLP-1),Recombinant and Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB13928,https://www.ema.europa.eu/en/documents/assessment-report/ozempic-epar-public-assessment-report_en.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf,https://patents.google.com/patent/CN112028986A/en ,,,,,,,"H, OH",True
Bremelanotide,Therapeutic,used to treat hypoactive sexual desire disorder in premenopausal women,Ac-XDHfRWK,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CN=CN2)NC1=O)C(O)=O,A,B,1025.182,7,5,1,yes,6,side chain-to-side chain (amide Lys-Asp),no,no,9720.0,21%,100%,SC,US,FDA,2019,Analogue,Alpha-melanocyte stimulating hormone (α-MSH),Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB11653,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf,https://patents.google.com/patent/CN106589111A/en ,,,,,,,,"acetyl, OH",True
Glutathione,Therapeutic,"For nutritional supplementation, also for treating dietary shortage or imbalance",gGlu-CG,N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O,A,B,307.32,3,3,0,no,N.A.,N.A.,no,no,600.0,-,"Research suggests that glutathione is not orally bioactive, and that very little of oral glutathione tablets or capsules is actually absorbed by the body.",ORAL,-,-,-,Natural,Glutathione,Fermentation,https://go.drugbank.com/drugs/DB00143,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779265/,https://patents.google.com/patent/US6902912B2/en ,,,,,,,,"H, OH",True
Bleomycin,Therapeutic,"For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.",-,CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O,B,B,1415.55,N.A.,N.A.,N.A.,no,N.A.,N.A.,no,yes - 2 sugars,6900.0,1%,45%,"IM, IV, SC, IP, IA, IC",US,FDA,1973,Natural,Streptomyces verticillus,Fermentation and Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB00290,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050443s036lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050443,https://pubmed.ncbi.nlm.nih.gov/14758754/ ,,,,,,,"N.A., N.A.",True
Colistin,Therapeutic,"For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.",XXT-XX(1)XlLXXT(1),CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O,A,B,1155.455,11,3,1,yes,7,head-to-side chain (Thr-Dab),yes,no,18000.0,-,Peak serum levels after intravenous (i.v.) administration are achieved within 10 min. They appeared higher but declined more rapidly than those achieved after i.m. administration,AURICULAR,US,FDA,1962,Natural,Bacillus polymyxa,Fermentation,https://go.drugbank.com/drugs/DB00803,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224467/,https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:37943,https://pubchem.ncbi.nlm.nih.gov/compound/Colistin,https://drugs.ncats.io/drug/Z67X93HJG1,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050356,,,,,"5-methyl-heptanoyl, cycle",True
Cyclosporine,Therapeutic,"Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. Secondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone. Off-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura",XXXXVXAaXXX,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,A,B,1202.635,11,2,1,yes,11,head-to-tail,no,no,68400.0,About 50% of the administered dose is taken up by erythrocytes while about 34% is bound to lipoproteins. Prescribing information for Sandimmune states that 90% is mainly bound to lipoproteins.,30%,"TOPICAL, OPHTALMIC, IV, ORAL",US,FDA,1983,Natural,Tolypocladium inflatum,Fermentation and Synthesis,https://go.drugbank.com/drugs/DB00091,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050715s027,050716s028lbl.pdf",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050574,https://pubs.acs.org/doi/10.1021/ja100517v ,,,,,,,"cycle, cycle",True
Dactinomycin,Therapeutic,"For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen",vPXXTXTXXPv,C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C,A,A,1255.438,11,4,2,yes,bicyclic,head-to-side chain (Val-Thr),no,no,129600.0,5%,Poorly absorbed from gastrointestinal tract,IV,US,FDA,1964,Natural,Product of fermentation by Streptomyces parvulus.,Fermentation,https://go.drugbank.com/drugs/DB00970,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050682s025lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050682s033lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050682,,,,,,,"2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarbonyl , cycle",True
Romidepsin,Therapeutic,For the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. ,vcXVXX,C/C=C/1\NC(=O)[C@H]2CSSCC/C=C/[C@@H](OC(=O)[C@@H](NC1=O)C(C)C)CC(=O)N[C@@H](C(=O)N2)C(C)C,A,B,540.69,5,1,2,yes,multicyclic,side chain-to-side chain (disulfide) + head-to-tail,no,no,10800.0,92-94%,-,IV,US,FDA,2009,Natural,Chromobacterium violaceum,Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB06176,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163831/,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022393lbl.pdf,https://pubchem.ncbi.nlm.nih.gov/compound/Romidepsin#section=3D-Conformer,https://patents.google.com/patent/CN111333697B/en ,,,,,,"cycle, cycle",True
Secretin porcine,Diagnostic,Secretin porcine stimulates pancreatic and gastric secretions to aid in the diagnosis of pancreatic exocrine dysfunction and the diagnosis of gastrinoma.,HSDGTFTSELSRLRDSARLQRLLQGLV-NH2,C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CN=CN2)N)O,A,B,3055.457,27,27,0,no,N.A.,N.A.,no,no,1620.0,-,-,IV,US,FDA,2002,Natural,-,Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB09527,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021136s012s013_021209s002lbl.pdf,https://pubmed.ncbi.nlm.nih.gov/838532/ ,,,,,,,,"H, NH2",True
Vancomycin,Therapeutic,"Treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. Additionally, a unique FDA approved oral liquid treatment is also available and indicated for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains",-,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,B,B,1449.27,N.A.,N.A.,N.A.,yes,multicyclic,C-C; C-O,no,yes - 2 sugars,21600.0,50%,Oral vancomycin has a bioavailability of less than 10%. Onset of action: Vancomycin has a rapid onset of action with a serum peak concentration immediately following the completion of the intravenous infusion.,"IV, ORAL",US,FDA,1958,Natural,Streptomyces orientalis,Fermentation,https://go.drugbank.com/drugs/DB00512,"https://www.ncbi.nlm.nih.gov/books/NBK459263/#:~:text=Absorption%3A%20Oral%20vancomycin%20has%20a,completion%20of%20the%20intravenous%20infusion.",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050671s024lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050671s010lbl.pdf,https://www.nature.com/articles/ja2014111,,,,,,"CH3, OH",True
Macimorelin,Diagnostic,Indicated for the diagnosis of adult growth hormone deficiency (AGHD),XwX,CC(C)(C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)NC=O)N,A,B,474.565,3,0,1,no,N.A.,N.A.,no,no,14759.999999999998,-,Oral bioavailability<1%,ORAL,US,FDA,2017,Heterologous,"Growth hormone secretagogue receptor agonist, ghrelin ",Synthesis,https://go.drugbank.com/drugs/DB13074,https://www.ema.europa.eu/en/documents/product-information/macimorelin-aeterna-zentaris-epar-product-information_en.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/205598Orig1s000PharmR.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/205598Orig1s000SumR.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205598s000lbl.pdf,,,,,,"H, N-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-acetate",True
Dotatate Gallium Ga-68,Diagnostic,Dotatate gallium 68 is one of the most prominent radiopharmaceuticals used in imaging with positron emission tomography. It binds to the somatostatin-2 receptor which is usually overexpressed in many neuroendocrine tumors in both adult and pediatric patients.,XFCYWKTCT,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O,A,A,1502.33,9,8,0,yes,6,side chain-to-side chain (disulfide),no,no,4080.0,It presents binding to plasma proteins,-,IV,US,FDA,2016,Analogue,somatostatin-2 receptor Analogue,-,https://go.drugbank.com/drugs/DB13925,https://www.fda.gov/news-events/press-announcements/fda-approves-new-diagnostic-imaging-agent-detect-rare-neuroendocrine-tumors,,,,,,,,,"DOTA, OH",True
Dalbavancin,Therapeutic,"Dalbavancin for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI), caused by susceptible isolates of the following gram-positive microorganisms:",-,CC(C)CCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)NC(C7=C(C(=CC(=C7)O)O[C@@H]8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=C(C(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC=C(O3)C=C2)C(=O)N1)NC)O)O)Cl)O)C(=O)NCCCN(C)C)O)Cl)C(=O)O)O)O,B,B,1816.71,N.A.,N.A.,N.A.,yes,multicyclic,C-O-C; C-C,yes,yes - 2 sugars,1245600.0,93%,"Due to its poor oral bioavailability, it is available only in an intravenous formulation",IV,US,FDA,2014,Analogue,vancomycin and teicoplanin,Semisynthesis (fermentation + synthesis),https://go.drugbank.com/drugs/DB06219,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503664/,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021883s003lbl.pdf,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021883s000lbl.pdf,,,,,,,"CH3, N.A.",True
Betiatide,Diagnostic,"Renal imaging agent to assess renal function. It is a diagnostic aid in providing renal function, split function, renal angiograms, and renogram curves for whole kidney and renal cortex.",XXGGG,C1=CC=C(C=C1)C(=O)SCC(=O)NCC(=O)NCC(=O)NCC(=O)O,A,B,367.38,5,3,0,no,N.A.,N.A.,no,no,21672.0,89%,-,IV,US,FDA,1990,Heterologous,-,-,https://go.drugbank.com/drugs/DB14082,https://www.webmd.com/drugs/2/drug-174979/kit-for-preparation-tc-99m-mertiatidebetiatide-intravenous/details,https://www.drugs.com/pro/technescan-mag3.html,https://apps.who.int/phint/pdf/b/6.3.2.20.Technetium-(99mTc)-mertiatide-complex-injection-(T_.pdf,https://drugs.ncats.io/drug/9NV2SR34P8,,,,,,"benzoyl-deamino-Cys, OH",True
Edotreotide gallium Ga-68,Diagnostic,Edotreotide gallium Ga-68 is a radioactive diagnostic compound used in positron emission tomography (PET) for diagnose somatostatin receptor positive neuroendocrine tumors in pediatrics and adults,XFCYWKTCX,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@H](CO)[C@@H](C)O)O.[68Ga+3],A,A,1486.55,9,7,0,yes,6,side chain-to-side chain (disulfide),no,no,4080.0,Data suggests edotreotide gallium-Ga 68 may bind to proteins in serum,"Edotreotide gallium Ga-68 reaches 80% activity in tumors within 30 minutes, and reaches its highest activity in tumors 70±20min post injection. ",IV,US,FDA,2019,Analogue,Somatostatin,Synthesis,https://go.drugbank.com/drugs/DB15494,https://www.ema.europa.eu/en/documents/assessment-report/somakit-toc-epar-public-assessment-report_en.pdf,,,,,,,,,"DOTA, 2-aminobutane-1,3-diol",True
Paritaprevir,Therapeutic,"Chronic Hepatitis C virus (HCV) infection in combination with Ombitasvir, Dasabuvir, and Ritonavir.",-,CC1=CN=C(C=N1)C(=O)N[C@H]2CCCCC/C=C\[C@@H]3C[C@]3(NC(=O)[C@@H]4C[C@H](CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8,A,B,765.89,6,0,0,yes,3,alkene,no,no,19800.0,97 to 98.6% bound to human plasma proteins,50%,ORAL,US,FDA,2014,Heterologous,-,Synthesis,https://go.drugbank.com/drugs/DB09297,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654544/,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206619,https://pubchem.ncbi.nlm.nih.gov/compound/Paritaprevir,,,,,,,"5-methyl-pyrazinoyl, cyclopropanesulfonamide",True
Grazoprevir,Therapeutic,"Grazoprevir is indicated in combination with Elbasvir (as the fixed dose combination product Zepatier) with or without Ribavirin for treatment of chronic HCV genotypes 1a, 1b, or 4 infection in adults.",-,CC(C)(C)[C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCC[C@@H]7C[C@H]7OC(=O)N1,B,B,766.91,5,0,0,yes,3,side chain-to-tail,no,no,111600.0,98.8%,27%,ORAL,US,FDA,2016,Heterologous,-,-,https://go.drugbank.com/drugs/DB11575,https://www.fda.gov/news-events/press-announcements/fda-approves-zepatier-treatment-chronic-hepatitis-c-genotypes-1-and-4,,,,,,,,,"cycle, cyclopropanesulfonamide",True
Voxilaprevir,Therapeutic,"Vosevi (Voxilaprevir/Sofosbuvir/Velpatasvir) is approved for use in patients with chronic Hepatitis C genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection who have previously been treated with an HCV regimen containing Sofosbuvir without an NS5A inhibitor",-,CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C,A,B,868.94,5,0,0,yes,3,side chain-to-tail,no,no,118800.0,Voxilaprevir is more than 99% bound to human plasma proteins,-,ORAL,US,FDA,2017,Heterologous,-,-,https://go.drugbank.com/drugs/DB12026,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209195s000lbl.pdf,,,,,,,,,"cycle, cyclopropanesulfonamide",True
Dotatate Copper Cu-64,Diagnostic,Used in molecular radiotherapy and positron emission tomography.,XFCYWKTCT,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[64Cu+2],A,A,1497.55,9,4,0,yes,N.A.,N.A.,no,no,45720.0,-,-,IV,US,FDA,2020,Analogue,Somatostatin,-,https://go.drugbank.com/drugs/DB15873,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-detectnet,,,,,,,,,"DOTA, OH",True
Voclosporin,Therapeutic,Used in combination with a background immunosuppressive regimen for the treatment of lupus nephritis,XXXXVXAaXXX,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,A,B,1214.646,11,2,1,yes,11,head-to-tail,yes,no,108000.0,97%,-,ORAL,US,FDA,2021,Analogue,Semisynthetic structural analogue of cyclosporine A,Semisynthesis,https://go.drugbank.com/drugs/DB11693,https://www.sciencedirect.com/topics/medicine-and-dentistry/voclosporin,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335848/,,,,,,,,"cycle, cycle",True
Dasiglucagon,Therapeutic (orphan),Glucagon analog used to treat severe hypoglycemia in pediatric and adult patients with diabetes.,HSQGTFTSDYSKYLDXARAEEFVKWLEST,C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)NC(C)(C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC=N7)N)O,A,B,3381.664,29,28,0,no,N.A.,N.A.,no,no,1800.0,-,-,SC,US,FDA,2017 (orphan) - 2021,Analogue,Glucagon,-,https://go.drugbank.com/drugs/DB15226 ,https://pubchem.ncbi.nlm.nih.gov/compound/Dasiglucagon#section=Isomeric-SMILES,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214231 ,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf,,,,,,,"H, OH",True
Odevixibat,Therapeutic,Odevixibat is an ileal sodium/bile acid cotransporter inhibitor indicated in the treatment of pruritus in patients with progressive familial intrahepatic cholestasis.,-,CCCCC1(CN(C2=CC(=C(C=C2S(=O)(=O)N1)OCC(=O)N[C@H](C3=CC=C(C=C3)O)C(=O)N[C@@H](CC)C(=O)O)SC)C4=CC=CC=C4)CCCC,A,B,740.93,3,0,1,no,N.A.,N.A.,no,no,8496.0,"Due to low systemic absorption of odevixibat, plasma protein binding studies could not be performed in vivo. In vitro, data suggests >99% protein bound.",Poor bioavailability. Majority of adult and pediatric patients do not have detectable plasma concentrations after administration.,ORAL,US-EU,EMA - FDA,2021,Heterologous,-,Synthesis,https://go.drugbank.com/drugs/DB16261,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215498s000lbl.pdf,https://www.ema.europa.eu/en/medicines/human/EPAR/bylvay,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550539/ ,,,,,,,"small molecule, OH",True
Trofinetide,Therapeutic,Trofinetide treats Rett Syndrome by reducing brain inflammation and preventing overactivation of certain types of cells.,GXE,C[C@]1(CCCN1C(=O)CN)C(=O)N[C@@H](CCC(=O)O)C(=O)O,A,B,315.14,3,2,0,no,N.A.,N.A.,no,no,5400.0,<6%,"At least 84% of the administered dose was absorbed following oral administration of 12,000 mg of Trofinetide.","ORAL, GASTROSTOMY",US,FDA,2023,Analogue,Neuroprotective analogue of glypromate,Synthetic,https://go.drugbank.com/drugs/DB06045,https://pubchem.ncbi.nlm.nih.gov/compound/11318905#section=3D-Conformer,https://daybue.com/daybue-pi.pdf,https://patents.google.com/patent/WO2021026066A1/en,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217026s000lbl.pdf,,,,,,"H, OH",True
Nirmatrelvir,Therapeutic,Nirmatrelvir is an oral protease inhibitor for the treatment of mild-to-moderate COVID-19.,XXXX,CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(F)(F)F)C(=O)N[C@@H](C[C@@H]3CCNC3=O)C#N)C,A,B,499.5,2,0,0,no,N.A.,N.A.,no,no,21780.0,69%,"Bioavaibility improved when administered with ritonavir. Median Tmax at 3 hours, with 2.21 mg/mL avaiable upon single oral dose of 300 mg.",ORAL,US,FDA,2023,,,Synthetic,https://go.drugbank.com/drugs/DB16691 ,https://pubchem.ncbi.nlm.nih.gov/compound/Nirmatrelvir ,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s000lbl.pdf ,https://pubs.acs.org/doi/10.1021/acs.orglett.2c03683 ,,,,,,,"trifluoroacetyl, (R)-2-methyl-3-((R)-2-oxopyrrolidin-3-yl)propanenitrile",True
Zilucoplan,Therapeutic,Zilucoplan is a complement inhibitor used to treat generalised myasthenia gravis in anti-acetylcholine receptor antibody-postive adults,Ac-KVERFDXXYXEYPXKXgX,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@H](C1CCCCC1)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC4=CNC5=C4C=CC=N5)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(=O)O)N(C)C(=O)[C@@H]7CC(=O)NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N7)CC8=CC=CC=C8)CCCNC(=N)N)CCC(=O)O)C(C)C)NC(=O)C)C(=O)O,A,B,3562.23,18,12,0,yes,6,head-to-tail,yes,no,619200.0,>99%,Peak plasma concentration ranges between 3 to 6 hours from 0.3 mg/kg dose via subcutaneous administration. Daily administration provides a steady state of concentration by 4 weeks of treatment. Less than 1% is execreted from urine and feces.,SC ,US,FDA,2023,,,Synthesis - Solid Phase Peptide Synthesis,https://go.drugbank.com/drugs/DB15636 ,https://pubchem.ncbi.nlm.nih.gov/compound/Zilucoplan#section=2D-Structure ,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216834s000lbl.pdf ,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781173/ ,,,,,,,"acetyl, OH",True
Danicopan,Therapeutic,Danicopan is a complement factor D inhibitor used to treat extravascular hemolysis in patients that have paroxysmal nocturnal hemoglobinuria.,X-GXX,CC1=NC=C(C=N1)C2=CC3=C(C=C2)N(N=C3C(=O)C)CC(=O)N4C[C@@H](C[C@H]4C(=O)NC5=NC(=CC=C5)Br)F,A,B,580.4 ,2,1,0,no,N.A.,N.A.,no,no,28440.0,91.5% - 94.3%,Median Tmax is 3.7 hours after oral administration of 150 mg.,ORAL,US,FDA,2024,,,Synthetic,https://go.drugbank.com/drugs/DB15401 ,https://pubchem.ncbi.nlm.nih.gov/compound/Danicopan#section=InChI,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624268/ ,,,,,,,,"1-(5-(2-methylpyrimidin-5-yl)-1H-indazol-3-yl)ethan-1-one, 6-bromopyridin-2-amine",True
